Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
Cole
Andrew
A
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006291:Health Policy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D000069283:Rituximab; D012657:Self-Help Groups; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000068879:Adalimumab